Q3 EPS Forecast for Astria Therapeutics Raised by Analyst

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Analysts at Wedbush upped their Q3 2025 earnings per share estimates for Astria Therapeutics in a report released on Wednesday, August 13th. Wedbush analyst L. Chico now anticipates that the biotechnology company will post earnings of ($0.28) per share for the quarter, up from their prior estimate of ($0.60). The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.65) per share. Wedbush also issued estimates for Astria Therapeutics’ Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($1.97) EPS, Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.50) EPS, FY2026 earnings at ($1.95) EPS, FY2027 earnings at ($2.22) EPS, FY2028 earnings at ($1.54) EPS and FY2029 earnings at $2.19 EPS.

Astria Therapeutics (NASDAQ:ATXS) last posted its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.04.

ATXS has been the topic of a number of other research reports. Citigroup restated an “outperform” rating on shares of Astria Therapeutics in a research report on Wednesday. HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a research report on Wednesday. JMP Securities lifted their target price on Astria Therapeutics from $25.00 to $26.00 and gave the company a “market outperform” rating in a research report on Wednesday. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $47.00 target price on shares of Astria Therapeutics in a research report on Wednesday, May 14th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Astria Therapeutics currently has an average rating of “Buy” and an average price target of $29.00.

Astria Therapeutics Stock Up 1.3%

NASDAQ:ATXS opened at $6.85 on Friday. Astria Therapeutics has a 52 week low of $3.56 and a 52 week high of $12.92. The company has a market capitalization of $386.61 million, a P/E ratio of -3.41 and a beta of 0.48. The stock’s fifty day moving average is $6.23 and its two-hundred day moving average is $5.76.

Institutional Investors Weigh In On Astria Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Tower Research Capital LLC TRC increased its holdings in Astria Therapeutics by 109.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 2,766 shares during the period. Farther Finance Advisors LLC increased its holdings in Astria Therapeutics by 185.8% during the 2nd quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 3,557 shares during the period. BNP Paribas Financial Markets purchased a new stake in Astria Therapeutics during the 4th quarter worth about $50,000. Virtus ETF Advisers LLC purchased a new stake in Astria Therapeutics during the 4th quarter worth about $65,000. Finally, GAMMA Investing LLC increased its holdings in Astria Therapeutics by 1,127.4% during the 1st quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 7,971 shares during the period. Hedge funds and other institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.